Cytokinetics Inc Cash Flow Conversion Efficiency
Cytokinetics Inc cash flow conversion efficiency. Based on the latest financial reports, Cytokinetics Inc (CYTK) has a cash flow conversion efficiency ratio of 0.921x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-159.84 Million) by net assets ($-173.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cytokinetics Inc market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Cytokinetics Inc (2002–2025)
Cash flow conversion efficiency of Cytokinetics Inc from 2002 to 2025. This chart illustrates how Cytokinetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CYTK share price today for real-time trading data and today's change.
Cytokinetics Inc Cash Flow Conversion Ratio Explained
Cytokinetics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cytokinetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytokinetics Inc ranked by their cash flow conversion efficiency. Review Cytokinetics Inc (CYTK) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
InterDigital Inc
NASDAQ:IDCC
|
0.069x |
|
Element Solutions Inc
NYSE:ESI
|
0.033x |
|
Pharmaron Beijing Co Ltd
SHE:300759
|
0.068x |
|
Shanghai International Airport Co Ltd
SHG:600009
|
0.041x |
|
Petronas Gas Bhd
KLSE:6033
|
0.061x |
|
BUNZL PLC ADR/ LS-3214857
F:BUZ
|
N/A |
|
GMéxico Transportes S.A.B. de C.V
MX:GMXT
|
0.114x |
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP
|
0.034x |
Annual Cash Flow Conversion Efficiency for Cytokinetics Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Cytokinetics Inc from 2002 to 2025. Also see how large is Cytokinetics Inc's balance sheet for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-659.62 Million | $-510.01 Million | 0.773x | -73.56% |
| 2024-12-31 | $-135.37 Million | $-395.89 Million | 2.924x | +172.68% |
| 2023-12-31 | $-386.32 Million | $-414.33 Million | 1.073x | -61.36% |
| 2022-12-31 | $-107.90 Million | $-299.52 Million | 2.776x | +574.97% |
| 2021-12-31 | $243.86 Million | $-142.52 Million | -0.584x | -840.97% |
| 2020-12-31 | $113.38 Million | $8.94 Million | 0.079x | -99.05% |
| 2019-12-31 | $-10.94 Million | $-90.91 Million | 8.312x | +312.97% |
| 2018-12-31 | $25.93 Million | $-101.22 Million | -3.903x | -321.28% |
| 2017-12-31 | $109.84 Million | $-101.76 Million | -0.926x | -336.38% |
| 2016-12-31 | $94.36 Million | $36.98 Million | 0.392x | +450.52% |
| 2015-12-31 | $68.59 Million | $4.88 Million | 0.071x | +114.62% |
| 2014-12-31 | $92.06 Million | $-44.84 Million | -0.487x | -243.58% |
| 2013-12-31 | $54.44 Million | $-7.72 Million | -0.142x | +69.71% |
| 2012-12-31 | $71.44 Million | $-33.44 Million | -0.468x | +50.54% |
| 2011-12-31 | $48.18 Million | $-45.59 Million | -0.946x | -48.86% |
| 2010-12-31 | $70.52 Million | $-44.83 Million | -0.636x | -866.19% |
| 2009-12-31 | $101.43 Million | $8.42 Million | 0.083x | +106.73% |
| 2008-12-31 | $49.77 Million | $-61.33 Million | -1.232x | -3997.48% |
| 2007-12-31 | $99.92 Million | $-3.00 Million | -0.030x | +93.22% |
| 2006-12-31 | $106.31 Million | $-47.17 Million | -0.444x | +17.34% |
| 2005-12-31 | $73.56 Million | $-39.48 Million | -0.537x | -69.64% |
| 2004-12-31 | $107.56 Million | $-34.03 Million | -0.316x | -195.43% |
| 2003-12-31 | $-92.03 Million | $-30.51 Million | 0.332x | -9.93% |
| 2002-12-31 | $-60.59 Million | $-22.30 Million | 0.368x | -- |
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral… Read more